

Mouse Anti-EBV Early Antigen [1108-1]: MC0039, MC0039RTU7

Intended Use: For Research Use Only

Description: Epstein-Barr virus (EBV), also designated human herpesvirus 4 (HHV-4), is one of eight known viruses in the herpes family, and is one of the most common viruses in humans. EBV infects B cells and, though often asymptomatic, it can cause infectious mononucleosis, a disease characterized by fatigue, fever, sore throat and muscle soreness. The EBV-induced early antigens (Ea) are among several antigen complexes that have been identified in EBV-infected cells. The Ea complex is composed of diffuse (Ea-D) and restricted (Ea-R) components. The activity of Ea-D is suppressed during latent infection. BMRF1, the gene that encodes for Ea-D, is closely associated with the gene encoding for EBV DNA polymerase, and Ea-D is essential for the activity of this polymerase. Ea-D forms a complex with EBV DNase and, together, they may play a role in viral replication.

Specifications


Clone: 1108-1
 Source: Mouse
 Isotype: IgG1k
 Reactivity: EBV Ea-D
 Immunogen: Affinity Purified early antigen polypeptides from induced Raji cells precipitated with African Burkitt's lymphoma sera
 Localization: Nucleus
 Formulation: Purified antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
 Storage: Store at 2°- 8°C
 Applications: IHC-Frozen or Paraformaldehyde/acetone-fixed cells, ICC/IF, IP
 Package:

Description	Catalog No.	Size
EBV Early Antigen Concentrated	MC0039	1 ml
EBV Early Antigen Prediluted	MC0039RTU7	7 ml

IHC Procedure*

Positive Control Tissue: EBV-infected cells or tissues
 Concentrated Dilution: 50-200
 Pretreatment: None
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



Activated Raji cells stained with anti-EBV Early Antigen using ARC

References

1. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. Carpentier L, et al. J Infect Dis. Dec 15;188(12):1853-64, 2003.
2. Biochemical characterization of two Epstein-Barr virus early antigen-associated phosphopolypeptides. Roeckel D, Mueller-Lantzsch N. Virology. 1985 Dec;147(2):253-63, 1985.